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Prediction of venetoclax activity in
precursor B-ALL by functional assessment
of apoptosis signaling
Felix Seyfried1, Salih Demir1,2, Rebecca Louise Hörl1, Felix Uli Stirnweiß1,2, Jeremy Ryan 3, Annika Scheffold4,
Mariana Villalobos-Ortiz3, Elena Boldrin1,2, Julia Zinngrebe1, Stefanie Enzenmüller1, Silvia Jenni5, Yi-Chien Tsai5,
Beat Bornhauser5, Axel Fürstberger6, Johann Michael Kraus6, Hans Armin Kestler6, Jean-Pierre Bourquin5,
Stephan Stilgenbauer4, Anthony Letai3, Klaus-Michael Debatin1 and Lüder Hinrich Meyer1
Abstract
Deregulated cell death pathways contribute to leukemogenesis and treatment failure in B-cell precursor acute
lymphoblastic leukemia (BCP-ALL). Intrinsic apoptosis signaling is regulated by different proapoptotic and
antiapoptotic molecules: proapoptotic BCL-2 homology domain 3 (BH3) proteins activate prodeath molecules leading
to cellular death, while antiapoptotic molecules including B-cell lymphoma 2 (BCL-2) prevent activation of prodeath
proteins and counter-regulate apoptosis induction. Inhibition of these antiapoptotic regulators has become a
promising strategy for anticancer treatment, but variable anticancer activities in different malignancies indicate the
need for upfront identiﬁcation of responsive patients. Here, we investigated the activity of the BCL-2 inhibitor
venetoclax (VEN, ABT-199) in B-cell precursor acute lymphoblastic leukemia and found heterogeneous sensitivities in
BCP-ALL cell lines and in a series of patient-derived primografts. To identify parameters of sensitivity and resistance, we
evaluated genetic aberrations, gene-expression proﬁles, expression levels of apoptosis regulators, and functional
apoptosis parameters analyzed by mitochondrial proﬁling using recombinant BH3-like peptides. Importantly, ex vivo
VEN sensitivity was most accurately associated with functional BCL-2 dependence detected by BH3 proﬁling. Modeling
clinical application of VEN in a preclinical trial in a set of individual ALL primografts, we identiﬁed that leukemia-free
survival of VEN treated mice was precisely determined by functional BCL-2 dependence. Moreover, the predictive
value of ex vivo measured functional BCL-2 dependence for preclinical in vivo VEN response was conﬁrmed in an
independent set of primograft ALL including T- and high risk-ALL. Thus, integrative analysis of the apoptosis signaling
indicating mitochondrial addiction to BCL-2 accurately predicts antileukemia activity of VEN, robustly identiﬁes VEN-
responsive patients, and provides information for stratiﬁcation and clinical guidance in future clinical applications of
VEN in patients with ALL.
Introduction
Although survival rates of pediatric B-cell precursor
acute lymphoblastic leukemia (BCP-ALL) patients have
improved during the past decades, therapy-related
toxicity and relapse occur in 10–20% of patients and
are associated with a poor outcome, clearly emphasizing
the need for novel, targeted treatment strategies1,2.
Deregulation of survival and cell death pathways are
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hallmarks of cancer3, particularly of BCP-ALL4,5, and
contribute to treatment failure and disease reoccur-
rence. B-cell lymphoma 2 (BCL-2) family members are
key regulators of apoptosis and frequently over-
expressed in lymphoid malignancies6,7. Proapoptotic
BCL-2 homology domain 3 (BH3)-only proteins bind to
the BH3-binding domain of antiapoptotic BCL-2 family
members, activating intrinsic apoptosis signaling8. Small
molecule inhibitors like ABT-737 and the orally bioa-
vailable navitoclax (ABT-263) mimic the binding of
BH3-only proteins to the BH-3 domains of antiapoptotic
BCL-2, BCL-XL and BCL-W, thereby inducing apopto-
sis9,10. Navitoclax has shown antitumor activity in BCL-
2-dependent malignancies, however co-occurring
thrombocytopenia has limited its clinical application11.
Venetoclax (VEN, ABT-199) is a BH3-mimetic molecule
selectively targeting BCL-2 at low sub-nanomolar
binding afﬁnity, sparing BCL-XL and BCL-W therefore
not affecting platelets12. Upon binding of VEN to BCL-
2, proapoptotic proteins such as BIM are released acti-
vating downstream apoptosis signaling. However, can-
cer cells might sequester BIM and antagonize VEN-
induced apoptosis13.
VEN showed high activity in patients with relapsed,
17p-deleted chronic lymphocytic leukemia (CLL), lead-
ing to drug-approval for these patients11,14. In addition,
VEN showed clinical activity in other hematological
malignancies, including blastic plasmacytoid dendritic
cell neoplasm15, non-Hodgkin lymphoma16, acute
myeloid leukemia17, and early T-cell precursor ALL18.
In BCP-ALL, single-agent activity has been described in
different subtypes in cell line, patient and patient-
derived xenograft samples19–22. However, clinical
application of VEN in BCP-ALL has just started evalu-
ating the effects in patients with relapsed or refractory
disease (ClinicalTrials.gov)23,24. Hence, clinical response
data and consequently information on potential markers
reﬂecting VEN sensitivity of individual patients will only
be available after some time. Nevertheless, reliable
upfront identiﬁcation of patients who would potentially
beneﬁt from strategies targeting BCL-2 is mandatory for
decision-making and therapy guidance of individual
patients in future evaluation and clinical application of
VEN in ALL patients.
In this study, we investigated VEN activity in a series of
B-ALL cell lines and patient-derived xenografts and
analyzed different leukemia characteristics with respect
to VEN sensitivity. We identiﬁed that functional BCL-2
dependence of apoptosis signaling in ALL cells was the
best marker associated with VEN response analyzed in
isolated ALL cells ex vivo and, importantly, predicted
VEN activity in a preclinical in vivo trial in
xenografted mice.
Results
Heterogeneous VEN sensitivity in BCP-ALL
First, we investigated activity of the selective BCL-2
inhibitor VEN in a set of different BCP-ALL cell lines
(N= 6) and patient-derived xenografts (PDXs, N= 27).
Analysis of cellular viability after exposure to increasing
concentrations of VEN showed that four out of six cell
lines investigated were sensitive to BCL-2-inhibition with
half maximal effective concentrations (EC50) in the
nanomolar range (RS4;11: 24, KOPN-8: 148, UoCB6: 376,
REH: 438 nM), while the two other lines showed clearly
higher EC50 values at micromolar concentrations indi-
cating VEN insensitivity (RCH-ACV: 6.8, NALM-6:
11.3 µM) (Fig. 1a, Supplementary Table 1).
Next, we analyzed VEN sensitivities of all together 27
patient-derived xenograft leukemia samples. Twenty
(74%) showed cell death in response to VEN at nanomolar
concentrations with EC50 values ranging from 1.8 to
410 nM in contrast to insensitivity in seven samples (26%;
EC50 above 1 µM ranging from 2.2 to 5.5 µM) (Fig. 1b,
Supplementary Table 2). VEN responses were reevaluated
in two individual leukemias obtained from three con-
secutively transplanted recipients showing the same drug
sensitivities conﬁrming stability of drug sensitivity upon
serial re-transplantation in the model (Supplementary
Fig. 1). Moreover, we also addressed activity on healthy
white blood cells investigating peripheral blood mono-
nuclear cells obtained from three healthy donors, which
showed only minimal responses at high VEN concentra-
tions corresponding to EC50 values of insensitive leuke-
mias (1.1, 1.9, and 3.8 µM) (Fig. 1b). Thus, VEN shows
antileukemia activity in the majority of BCP-ALL samples;
however, sensitivities vary including a subset of leukemia
samples showing insensitivity.
VEN sensitivity is independent of recurrent genetic
alterations and leukemia characteristics
Given the heterogeneity of VEN responses observed in
individual leukemias and the diversity of precursor B-ALL
with different genetic alterations relevant for patient
outcome and treatment stratiﬁcation25,26, we addressed
whether speciﬁc leukemia characteristics including
genetic aberrations recurrently found in BCP-ALL are
associated with VEN sensitivity (Supplementary Fig. 2).
Immunophenotypes and patient gender were distributed
independently of VEN sensitivities, and similar VEN
sensitivities were seen in leukemias from patients with or
without relapse (U-test, P= 0.341) and no differences in
patient age were observed between VEN sensitive and
insensitive ALL samples (U-test, P= 0.464) (Supplemen-
tary Fig. 2A). Four of the leukemia samples were derived
from infants below one year of age and characterized by a
pro-B ALL immunophenotype and eitherMLL/AF4 (N= 1)
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orMLL/ENL (N= 3) gene fusions. TheMLL/AF4-positive
leukemia showed sensitivity to VEN (EC50 98.78 nM),
while the three MLL/ENL rearranged leukemias displayed
heterogeneous responses with EC50 values of 19, 49, and
5499 nM. Similarly, in ETV6/RUNX1 positive ALL (N=
6) heterogeneous VEN activities were observed with
EC50s ranging from 1.87 to 4359 nM. No TCF3/HLF,
IGH@/CRLF2 nor BCR/ABL positive cases were included
and only single cases were positive for P2RY8/CRLF2 or
TCF3/PBX1 fusions (Supplementary Fig. 2B). Further-
more, we analyzed copy number alterations recurrently
described in BCP-ALL. Most samples were characterized
by the presence of at least one copy number alteration
(Supplementary Fig. 2C). CDKN2A and CDKN2B were
most frequently affected; however, no differences in VEN
sensitivity were observed in samples with or without
CDKN2A or CDKN2B deletions (U-test, p= 0.867 and p
= 0.456) and no differences were found for the other
aberrations tested. Moreover, the presence of nucleotide
variants of genes was also not associated with responses to
VEN (Supplementary Fig 2D). Most importantly, we also
analyzed BCL2 but detected wild-type sequences in
all cases.
In order to get further insight into potential mechan-
isms of VEN responsiveness, we analyzed expression
proﬁles of VEN sensitive ALL samples (EC50 values below
100 nM, N= 12) compared to resistant leukemias (EC50
values above 1 µM, N= 7). The resulting signature of
differentially regulated genes (Supplementary Table 3) did
not show enrichment of genes coding for proteins
involved in cell death and apoptosis. In addition, pathway
annotation studies revealed that the VEN sensitivity/
resistance proﬁle was not associated with gene sets
annotated to cell death regulation or oncogenic pathways
(Supplementary Fig. 3).
VEN sensitivity is associated with expression levels of
mitochondrial apoptosis regulators
Next, we analyzed the impact of expression levels of
BCL-2, the direct target molecule of VEN, and of potential
mediators of response in BCP-ALL. In a mechanistic
concept, VEN binds to BCL-2 with high afﬁnity and
selectivity, thereby liberating BCL-2-bound, proapoptotic
proteins like BIM leading to induction of downstream
apoptosis signaling. In line with this concept, we found
that VEN sensitivity correlates with high gene-expression
levels of the target molecule BCL-2 (Table 1(a), Supple-
mentary Fig. 4) and as a trend on protein level (Table 1(b),
signiﬁcance level corrected for multiple testing). Inter-
estingly, the most sensitive leukemia with the lowest EC50
value (PDX1) showed the highest BCL-2 protein expres-
sion (Supplementary Fig. 5). On the other hand, other
antiapoptotic BCL-2 family members such as MCL-1,
BCL-XL, and BCL-W are able to bind and sequester
released proapoptotic regulators like BIM thereby coun-
teracting VEN-induced apoptosis. VEN might also inter-
fere with BCL-XL and BCL-W, but with a clearly lower
afﬁnity than with BCL-212. However, high transcript or
protein expression of MCL-1, BCL-XL, or BCL-W was
not clearly associated with VEN insensitivity (Table 1(a),
(b), Supplementary Fig. 4). Balancing the expression levels
of BCL-2 and the prosurvival molecules MCL-1, BCL-W,
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Fig. 1 Heterogeneous sensitivities for VEN in BCP-ALL. Cell death induction (ﬂow cytometry, forward/side scatter criteria) upon exposure of a
BCP-ALL cell lines (N= 6, 72 h; from left [low EC50, sensitive] to right [high EC50, insensitive]: RS4;11, KOPN-8, UoCB6, REH, RCH-ACV, and Nalm-6), b
patient-derived BCP-ALL xenograft samples (N= 27, 24 h, from left [low EC50, sensitive] to right [high EC50, insensitive]: PDX1, PDX2, …, PDX27) or
peripheral blood mononuclear cells from healthy donors (N= 3, dashed lines) to increasing concentrations of VEN (0.1, 1, 10, 50, 100, 250, 500 nM, 1,
3, 5, and 10 µM) showing heterogeneous half maximal effective concentrations (EC50) indicating variable VEN sensitivities of BCP-ALL. (See also
Supplementary Tables 1 and 2)
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or BCL-XL revealed a signiﬁcant association of VEN
sensitivity with high BCL-2/MCL-1 ratios on transcript
and protein level (i.e., high BCL-2/low MCL-1 expression;
Table 1(a), (b), Supplementary Fig. 4). Thus, these data
indicate that high expression of the target molecule BCL-
2, in particular along with low expression of the coun-
teracting molecule MCL-1, is related to VEN-mediated
apoptosis induction in BCP-ALL cells. Interestingly,
expression of the other prosurvival regulators BCL-XL
and BCL-W was not found to be clearly associated with
VEN sensitivity, neither alone nor in comparison to BCL-
2 (Table 1(a), (b), Supplementary Fig. 4). Moreover, BIM
levels were also not associated with VEN sensitivity and
the ratio of BCL-2 to BIM did not show a superior
association to VEN sensitivity than BCL-2 alone (Sup-
plementary Table 4).
Taken together, these data show that sensitivity to VEN
is not only determined by presence of the target molecule
BCL-2 alone but will rather be affected by the interaction
of different BCL-2 family members present in the leuke-
mia cell. However, this regulatory interplay will not be
sufﬁciently reﬂected by transcript or protein expression of
single molecules, but would require a comprehensive
analysis of the functional network of different signaling
molecules.
Functional dependence on BCL-2 determines VEN activity
As indicated above, VEN activity in BCP-ALL might be
inﬂuenced by different regulators of mitochondrial
apoptosis signaling. Therefore, we applied an integrative
analysis of the functional interplay of the different
apoptosis-regulating molecules investigating the depen-
dence of apoptosis signaling on different BCL-2 family
members at the mitochondrial level.
This method is based on synthetic BH3-only peptides or
small molecules, which speciﬁcally bind to different BCL-
2 family proteins involved in mitochondrial apoptosis
regulation (mitochondrial priming)27–30 followed by
assessment of apoptosis induction assaying mitochondrial
cytochrome c release as an early event in apoptosis sig-
naling (Fig. 2a, Supplementary Fig. 6). A panel of ﬁve
BH3-peptides (BIM, PUMA, BAD, HRK, and MS1)
binding to different antiapoptotic molecules, including
BCL-2, BCL-xl, BCL-W, and MCL-1, was used (Fig. 2b)
and in addition VEN itself. BIM and PUMA bind non-
speciﬁcally to antiapoptotic BCL-2 family proteins, BAD
binds to BCL-2, BCL-XL and BCL-W, but it does not
distinguish between these proteins, and HRK binds to
BCL-XL and MS1 to MCL-131. As expected, we found a
signiﬁcant correlation of direct VEN priming with VEN
sensitivity obtained upon ex vivo drug exposure and direct
VEN priming was predictive for VEN activity ex vivo (Fig.
2c, d). Interestingly, high mitochondrial priming induced
by the BAD peptide, which not only binds to BCL-2 but
also to BCL-XL and BCL-W, also showed a considerable
association with high ex vivo VEN sensitivity, although
not gaining statistical signiﬁcance (Table 2 and Fig. 2e).
To correct for the additional binding of the BAD peptide
to BCL-XL (Fig. 2b), subtraction of the response induced
by HRK from the BAD-response (BAD-HRK) had been
described, analyzing the role of BCL-2 and its cellular
dependency more precisely17,18. Interestingly, BAD-HRK
priming showed an association to transcript and protein
levels of BCL-2 (Supplementary Table 5) and a strong
association to VEN sensitivity (Table 2 and Fig. 2g).
Moreover, ex vivo VEN activity in ALL was more pre-
cisely predicted by BAD-HRK priming than by priming of
BAD alone (Fig. 2f, h). Thus, a strong functional depen-
dence of the leukemia cell on BCL-2 (BAD-HRK priming)
is highly indicative for ex vivo anti-ALL activity of VEN.
However, binding of antiapoptotic BCL-2 family mole-
cules by BIM and PUMA peptides and, importantly spe-
ciﬁc interference with MCL-1 and BCL-XL by MS1 or
HRK peptide did not show any clear association with VEN
sensitivity (Table 2 and Supplementary Fig. 7).
Table 1 Expression of BCL-2 family members and ex vivo
VEN sensitivity
R2 P
(a) Gene expression levelsa
BCL2/MCL1 0.390 0.0005*
BCL2 0.335 0.0016*
BCL2L2 0.327 0.0018*
MCL1 0.235 0.0104
BCL2/BCL2L1 0.119 0.0783
BCL2/BCL2L2 0.004 0.7608
BCL2L1 0.001 0.9063
(b) Proteins levelsb
BCL-2/MCL-1 0.542 0.0041*
BCL-2/BCL-XL 0.431 0.0147
BCL-2 0.354 0.0318
BCL-2/BCL-W 0.328 0.0409
MCL-1 0.243 0.0869
BCL-XL 0.132 0.2218
BCL-W 0.001 0.9405
R2, correlation coefﬁcient. Bonferroni-adjusted signiﬁcance level: P ≤ 0.05/7=
P ≤ 0.0071
*Indicates statistical signiﬁcance
aPatient-derived xenograft BCP-ALL (N= 27). Linear regression of EC50 of
venetoclax with the parameter indicated, sorted by signiﬁcance
bPatient-derived xenograft BCP-ALL (N= 13). Linear regression of EC50 of
venetoclax with the parameter indicated, sorted by signiﬁcance
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Preclinical VEN activity is indicated by functional BCL-2
dependence
Functional BCL-2 dependence (BAD-HRK priming)
showed the strongest association with individual VEN
sensitivities assessed by ex vivo drug exposure. To address
antileukemia activities of VEN in individual leukemia
samples in a situation more similar to a potential clinical
application, we investigated its antileukemia activities in a
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Fig. 2 Functional BCL-2 dependence indicates ex vivo VEN activity. Assaying the dependence of mitochondrial apoptosis signaling on different
regulating molecules interrogating binding of speciﬁc BH3 peptides (BH3 proﬁling). a Experimental procedure, ALL cells are permeabilized, incubated
with the respective peptide followed by detection of cytochrome c release. b Binding table showing interaction of the BH3-peptides (columns) with
the respective apoptosis-regulating molecule (rows). Mitochondrial priming by c VEN, e BAD, and g BAD-HRK is signiﬁcantly associated with ex vivo
venetoclax sensitivity (linear regression; R2, correlation coefﬁcient; p, signiﬁcance) and d, f, h predictive for ex vivo response of ALL cells to venetoclax
(ROC/receiver operating characteristic curve; AUC, area under the curve; p, signiﬁcance)
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preclinical phase-II-like trial on different individual,
patient-derived xenograft ALL samples in mice (N= 12).
Three weeks after transplantation onto recipient mice,
ALL-bearing animals were treated with VEN for 10 days
and times to reoccurrence of full-blown, clinically
apparent leukemia after treatment with VEN or vehicle
were compared for each leukemia. We observed distinct
in vivo antileukemia activities of VEN indicated by dif-
ferences of survival times (‘delta survival’) ranging from
minimal effects to prolonged survival without manifesta-
tion of ALL for more than 140 days (Fig. 3a). This var-
iation of in vivo responses is similar to the heterogeneity
of VEN sensitivities observed ex vivo, and EC50 values
analyzed ex vivo showed a moderate association with
in vivo survival times (Table 3, Supplementary Fig. 8).
We then analyzed whether the molecular markers
associated with ex vivo VEN response would indicate
in vivo antileukemia activity. No association of preclinical
VEN activity with BCL-2 expression was found, neither
alone nor relative to MCL-1 transcript levels (Table 3,
Supplementary Fig. 8). However, direct VEN priming was
associated with in vivo antileukemia activity of VEN
(Table 3 and Fig. 3b), but not predictive for in vivo VEN
activity (Fig. 3c). Interestingly, functional dependence of
the leukemia cells on BCL-2 (BAD-HRK priming) was
strongly associated with in vivo VEN activity (Table 3 and
Fig. 3d), and importantly, showed high sensitivity and
speciﬁcity in predicting preclinical in vivo antileukemia
activity of VEN (Fig. 3e).
To further corroborate our ﬁndings of the preclinical
trial, we investigated three primograft leukemias with
distinct responses to VEN (PDX#13, delta survival 0 days;
PDX#10, delta survival 34 days; and PDX#2, delta survival
> 138 days) in larger experimental treatment groups of
5–10 recipients. Upon leukemia manifestation (presence
of 5% human ALL cells in the recipients peripheral blood),
mice were treated with either VEN or vehicle for 10 days
followed by assessment of leukemia-free survival until
disease manifestation for each recipient. These results
obtained from larger groups of biological replicates pre-
cisely reﬂected the drug responses seen in the preclinical
trial and, importantly, clearly corresponded to the degree
of BCL-2 dependence assessed by mitochondrial priming:
(i) PDX13 showed a minor delay of disease manifestation
and low BCL-2 dependence (Fig. 3f, mean survival dif-
ference 2.3 days, BAD-HRK priming 18.6%), (ii) in PDX10
we observed a signiﬁcantly delayed onset of overt leuke-
mia upon VEN therapy in line with clear BCL-2 depen-
dence (Fig. 3g, mean survival difference 43.2 days, BAD-
HRK priming 56.8%), and (iii) PDX2 showed a prolonged
survival with no leukemia manifestation in the VEN group
within the observation period (Fig. 3h, more than 70 days
superior survival, BAD-HRK priming 80.3%) corre-
sponding to a strong BCL-2 dependence.
Moreover, we also analyzed mitochondrial priming in
leukemia cells of an independent cohort of patient-
derived ALL primografts, in which in vivo antileukemia
activity of VEN had been analyzed in a similar preclinical
xenograft mouse model21,32. This cohort of eight patient-
derived ALL samples comprises both, BCP- (N= 5) and
T- (N= 3) ALL samples, and also includes three BCP-
ALL cases carrying a TCF3/HLF gene fusion (Supple-
mentary Table 6), a genetic aberration associated with
very poor prognosis. Comparing the survival times of
VEN- and vehicle-treated animals, we found different
times indicating distinct in vivo VEN sensitivities of the
individual leukemias (Fig. 4a). Most importantly, also in
this cohort we found that functional BCL-2 dependence
of the leukemia cells measured by BAD-HRK priming is
signiﬁcantly associated with preclinical response (Fig. 4b)
predicting in vivo antileukemia VEN activity, in both
BCP- and T-ALL (Fig. 4c).
Thus, our ﬁndings show that interrogation of mito-
chondria with BH-3 mimetic peptides in ALL yields
molecular information on pathways providing criteria for
upfront identiﬁcation of patients responding to BCL-2
directed therapy, being of relevance for patient treatment
stratiﬁcation. Moreover, the advantage of a rapid analysis
time and quick availability of the result within few hours
strongly emphasizes the use and prospective evaluation of
this marker in future clinical application of VEN in ALL.
Discussion
The orally bioavailable BCL-2 inhibitor VEN has proven
effectiveness in chronic lymphocytic leukemia (CLL) and
other hematological malignancies11,14–18, and has been
implemented into regimens treating CLL patients33. In
ALL, application of VEN has just started in ﬁrst clinical
trials investigating activity in relapsed or refractory dis-
ease (ClinicalTrials.gov)24; however clinical response data,
Table 2 Association of mitochondrial proﬁling with
ex vivo VEN sensitivity
Parameter R2 P
BAD-HRK 0.587 0.0001*
VEN 0.384 0.0036*
BAD 0.317 0.0098
PUMA 0.212 0.0413
MS1 0.203 0.0465
HRK 0.140 0.1039
BIM 0.051 0.3404
Patient-derived xenograft BCP-ALL (N= 20). Linear regression of EC50 of
venetoclax with the parameter indicated, sorted by signiﬁcance. R2, correlation
coefﬁcient. Bonferroni-adjusted signiﬁcance level: P ≤ 0.05/7= P ≤ 0.0071
*Indicates statistical signiﬁcance
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particularly for de novo ALL, are not yet available. Thus,
rapid identiﬁcation of patients who would beneﬁt from
BCL-2-directed treatment is of major importance and
markers which best reﬂect antileukemia activity of VEN in
the situation of clinical application are strongly needed.
Investigating a series of 27 patient-derived BCP-ALL
samples, we titrated half maximal EC50 for each individual
leukemia. Variable responses were observed in different
patient-derived xenograft BCP-ALL samples with high
sensitivity at nanomolar drug concentrations and lower
sensitivity or no response, in line with heterogeneous
VEN sensitivities previously reported in BCP-ALL19,21,34.
Given this heterogeneity of responses to VEN among
different individual leukemias, we aimed to analyze mar-
kers indicating sensitivity to BCL-2 inhibition.
Clinical markers of the different leukemias established
for prognosis and therapy stratiﬁcation were not asso-
ciated with VEN sensitivity. In particular, recurrent
genetic alterations described in BCP-ALL including
aberrations in IKZF1, CDKN2A/B, and PAX5 were not
related to sensitivity. Previous reports described TCF3/
HLF rearranged BCP-ALL to be particularly sensitive to
VEN21,32, a rare BCP-ALL subgroup with dismal out-
come35. However none of the leukemias investigated in
Table 3 Functional dependence on BCL-2 assessed by
mitochondrial priming is associated with in vivo VEN
activity
Parameter R2 P
VEN 0.524 0.0078*
BAD-HRK 0.522 0.0080*
EC50 0.351 0.0423
BCL2/MCL1 (transcript) 0.337 0.0479
BCL-2/MCL-1 (protein) 0.311 0.0597
BCL2 (transcript) 0.180 0.1698
In vivo venetoclax treated patient-derived xenograft BCP-ALL (N= 12). Linear
regression of in vivo response (‘delta survival’) of venetoclax treated mice with
the parameter indicated, sorted by signiﬁcance. R2, correlation coefﬁcient.
Bonferroni-adjusted signiﬁcance level: P ≤ 0.05/6= P ≤ 0.0083
*Indicates statistical signiﬁcance
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mCD45−huCD45+huCD19+ or huCD7+) in the peripheral blood. a Survival times of leukemia bearing mice treated with VEN (gray bars) or vehicle
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BCL-2 dependence (mitochondrial BAD-HRK priming) with preclinical VEN sensitivities of ALL in vivo (linear regression; R2, correlation coefﬁcient; p,
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our initial analysis cohort carried this gene fusion. The
MLL/AF4 fusion was described to mediate high BCL-2
expression leading to VEN sensitivity34, and response was
reported in four out of four samples tested in an ex vivo
drug screen and in three out of six MLL/AF4 positive
leukemias upon in vivo treatment21,36. In our study, one
MLL/AF4 positive case was included, which was respon-
sive to VEN. On the other hand, two out of three MLL/
ENL rearranged cases were sensitive while one was the
most insensitive case in our cohort. Thus, in addition to
potential sensitivities in particular subgroups, we and
others showed various VEN activities across different
BCP-ALL subgroups including high sensitivities in many
cases, which are not characterized by established diag-
nostic markers21,34,36, further underlining the need for
independent determinants indicating VEN response.
VEN binds directly to BCL-2, leading to release of
proapoptotic molecules and apoptosis induction12. In line,
we found higher expression levels of the target molecule
BCL-2 in responsive leukemias, consistent with previously
reported results in BCP-ALL, T-ALL, and AML cell
lines34,37,38. Other BCL-2 family members like MCL-1 and
BCL-XL sequester proapoptotic regulators released from
BCL-2, thereby counteracting apoptosis induction13. In
line with this mechanism, we found low MCL-1 together
with high BCL-2 expression to be associated with VEN
sensitivity. Accordingly, high BCL-2 relative to low MCL-1
expression was reported to indicate BCL-2 inhibitor sen-
sitivity in multiple myeloma, mantle cell lymphoma and
Philadelphia-chromosome positive ALL39–41. However,
other studies did not observe associations of BCL-2 or
MCL-1 expression and drug sensitivity in ALL21,34. BCL-
XL, another antiapoptotic molecule, was described to have
regulatory impact counteracting sensitivity in a study
investigating VEN in ALL xenografts in vivo36. In contrast
to this, other studies did not observe an association of
BCL-XL and VEN activity, as we did also not ﬁnd a clear
connection of drug sensitivity with BCL-XL in our
cohort21,34. Analyzing expression of proapoptotic BIM, we
did not ﬁnd an association with VEN sensitivity in our
ALL model, suggesting that BIM levels do not sufﬁciently
explain VEN activity and emphasizing that a more com-
plex interplay of apoptosis regulators determines drug
sensitivity, as recently proposed for other BH3-mimetics42.
Thus, although indicative for single molecules, these dif-
ferent ﬁndings and variations of expression levels observed
in distinct studies clearly underline the limitations of
quantifying levels of single regulators or ratios as reliable
indicators for drug response.
Key apoptosis signaling pathways converge at the
mitochondrial level and are controlled by different proa-
poptotic and antiapoptotic molecules constituting a
functional regulatory network. Consequently, the activity
of therapeutic agents targeting speciﬁc mitochondrial
regulators, like VEN targets BCL-2, is not only deter-
mined by direct interference, but rather a result of the
interplay of involved molecules. In an integrative analysis,
we therefore interrogated mitochondrial apoptosis reg-
ulation using a panel of synthetic proapoptotic BH3-
peptides, which interact with the respective antiapoptotic
molecules and delineate their speciﬁc roles and the cell’s
addiction to particular regulators of mitochondrial
apoptosis signaling43. Analyzing the early apoptosis sig-
naling event mitochondrial cytochrome c release as a
readout, this assay provides results within few hours and
does not require culture of primary patient cells, which
might bias the analysis by high cell death rates upon
prolonged culture of primary ALL cells. We applied this
functional approach and observed that leukemia cells with
strong functional dependence on BCL-2 (BAD-HRK
priming) showed high VEN sensitivity upon ex vivo
exposure (low EC50 values), in line with previous reports
on BCL-2 dependence and VEN sensitivity measured in
isolated BCP-ALL and T-ALL cells17–19,34. However,
assessing drug sensitivities in isolated primary ALL cells
upon prolonged ex vivo culture is limited by high cell
death rates due to lacking or reduced cellular contact and
survival signals by a “death by default” mechanism44,45. In
line, clinical patient outcome upon speciﬁc treatment is
more accurately reﬂected by response evaluation of
patient-derived ALL modeled in vivo in a phase-II-like
preclinical trial46. Preclinical in vivo response was found
to be associated with direct VEN priming and, as pre-
viously reported, with ex vivo measured VEN
response21,36. However, comparing the associations and
predictive values of markers identiﬁed for ex vivo sensi-
tivity, we found that a clear dependency of mitochondrial
signaling on BCL-2 in the leukemia cell is strongly asso-
ciated with high response rates in vivo and, most impor-
tantly, most accurately predicts leukemia-free survival of
BCP-ALL. Importantly, this ﬁnding of a highly indicative
value of functional BCL-2 dependence for in vivo VEN
sensitivity was conﬁrmed in an independent set of pre-
clinically treated primograft samples and extended to T-
ALL and TCF3/HLF rearranged ALL, a rare subgroup
associated with early relapse and dismal outcome35, for
which in vitro and preclinical in vivo response to VEN had
recently been reported32.
Taken together, our ﬁndings underline the importance
to further investigate markers, which identify patients
who would beneﬁt from BCL-2-directed therapy. In our
study, we show that assaying the leukemia cell’s addiction
to BCL-2-mediated mitochondrial apoptosis signaling is a
rapid procedure providing biological information avail-
able in a short time accurately predicting VEN sensitivity,
which can be used for upfront identiﬁcation of responsive
patients and clinical guidance in future trials evaluating
VEN efﬁcacy in BCP-ALL.
Seyfried et al. Cell Death and Disease          (2019) 10:571 Page 9 of 12
Ofﬁcial journal of the Cell Death Differentiation Association
Materials and methods
ALL cell lines
Cell lines were obtained from DSMZ, Braunschweig,
Germany, UoCB6 cells were kindly provided by Dr J.
Rowley, Chicago, USA. Initially, cells were ampliﬁed,
authenticated by short tandem repeat proﬁling and tested
for Mycoplasma negativity by DAPI staining (5 min
DAPI-methanol 1:5000 in sterile PBS at room tempera-
ture, followed by washing with sterile PBS and micro-
scopy) and stocks were frozen. For experiments, cells were
thawed and used for analyses within 40 passages. Cells
were cultured in RPMI 1640 medium supplemented with
10–20% fetal bovine serum and L-Glutamine (Gibco Life
Technologies, Germany) at 37 °C in a humidiﬁed atmo-
sphere with 5% carbon dioxide.
ALL xenograft samples
Leukemia samples were obtained from pediatric
patients diagnosed with precursor B-ALL after informed
consent of patients and/ or their legal guardians in
accordance with the institution’s ethical review board. All
patients have been diagnosed and treated according to the
AIEOP-BFM protocols1. Primograft leukemias were
established by transplanting ALL cells onto female NOD/
SCID mice (NOD.CB17-Prkdcscid, Charles River, Ger-
many) as described earlier47,48. Immunophenotyping was
carried out following standard procedures analyzing cells
on a LSR II ﬂow cytometer (BD Bioscience, Germany). All
animal experiments were approved by the appropriate
authority (Regierungspräsidium Tübingen, Tierversuch
Nr. 1260).
Cell viability assays
Cell viability assays were performed upon culturing of
cells in RPMI 1640 supplemented with 20% FCS and 1%
L-glutamine. Cells were exposed to 11 different con-
centrations of VEN (0.1 nM, 1 nM, 10 nM, 50 nM,
100 nM, 250 nM, 500 nM, 1 µM, 3 µM, 5 µM, and 10 µM)
for 72 h (BCP-ALL cell lines) or 24 h (BCP-ALL PDX
cells). VEN was purchased from Chemietek (USA). Cell
viability and cell death were assessed on a BD FACSCa-
libur using forward/side scatter criteria. Half maximal
EC50 of VEN were analyzed for each sample.
In vivo treatment
Upon transplantation of ALL cells, engraftment of
human blasts was monitored in peripheral blood by ﬂow
cytometry surface staining for huCD19 and huCD4549,50.
Mice were treated with vehicle (60% Phosal 50 PG, 30%
polyethylene glycol and 10% ethanol) or VEN 100mg/kg/
day orally for 10 days. Treatment was initiated on day 21
post transplantation (Fig. 3a) or upon engraftment of
more than 5% blasts in the peripheral blood (Fig. 3f–h).
Posttreatment survival times were deﬁned as
manifestation of clinically overt leukemia in recipient
animals upon initiation of treatment. Manifestation of
leukemia was conﬁrmed by ﬂow cytometry staining of
bone marrow and spleen cells as described above showing
high percentages of human ALL in the respective com-
partments. For the independent cohort (Fig. 4) treatment
was carried out as previously described21,32.
Western blot analysis
Western blotting was performed as previously descri-
bed48. BCL-2 Mouse monoclonal antibody (BD Bios-
ciences, Germany), Mcl-1 Rabbit polyclonal antibody
(Stressgen, Canada), Bcl-w Rabbit monoclonal antibody
(Cell Signaling Technology, Germany), Bcl-xl Rabbit
monoclonal antibody (Cell Signaling Technology, Ger-
many), ß-Actin Mouse mononoclonal antibody, (Sigma-
Aldrich, Germany) and mouse anti-alpha-Tubulin
monoclonal antibody (Calbiochem, USA) were used as
primary antibodies, followed by goat anti-mouse IgG-HRP
or goat anti-rabbit IgG-HRP (Santa Cruz Biotechnology,
USA) secondary antibodies.
Genetic alterations
Deletions and ampliﬁcations were assessed by Multiplex
Ligation-dependent Probe Ampliﬁcation (MLPA; SALSA
MLPA P335-B2 ALL-IKZF1 probemix, MRC-Holland,
The Netherlands) according to the manufacturer’s
instructions. P2RY8-CRLF2 (primer: 5′-GGACAGATG
GAACTGGAAGG-3′ and 5′-GTCCCATTCCTGATGG
AGAA-3′), IGH@-CRLF2 (primer: 5′- AATACTTCCAG
CACT-3′ and 5′-GTCCCATTCCTGATGGAGAA-3′),
TCF3/PBX1 (primer: 5′-CACCAGCCTCATGCACAAC-3′
and 5′-TCGCAGGAGATTCATCACG-3′) and TCF3/
HLF (primer: 5′-TCCAGCCCTTCTACCCCCGTGG-3′
and 5′-GCATTTGCCCAGCTCCTTCCTCAA-3′) were
analyzed by RT-PCR as described earlier51. DNA
sequencing was performed using the TruSeq custom
amplicon kit (Illumina, San Diego, USA) according to the
manufacturer’s instructions. Reads were aligned to the
hg19 human reference genome. Variant calling ﬁles were
generated and custom R scripts were used for further
downstream analyses. Only variants with a variant allele
frequency cutoff of 0.2 were considered. For detection of
TP53 mutations, exons 4 to 10 (coding region of P53)
were analyzed by denaturing high-performance liquid
chromatography on a WAVE 3500HT System (ADS
Biotec, Glasgow, UK)52.
Gene-expression analysis
Gene expression was analyzed using Affymetrix U133
Plus 2.0 arrays as described before53. Gene-expression
data were deposited in the Gene Expression Omnibus
database of the National Center for Biotechnology Infor-
mation (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
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acc=GSE123883, GEO series accession number
GSE123883). To determine the expression of single genes,
the geometric mean of all probe sets mapping a gene was
calculated and log2 median-centered expression values
were analyzed. The following probe sets were used to
analyze transcript levels of apoptosis regulators (BCL2:
207004_at, 207005_s_at, 203684_s_at, and 203685_at),
(MCL1: 200796_s_at, 200797_s_at, 200798_x_at,
214056_at, 214057_at, and 227175_at), (BCL2L1:
206665_s_at, 231228_at, 212312_at, and 215037_s_at),
(BCL2L2: 1555140_a_at, and 209311_at), and (BCL2L11:
1553096_s_at, 222343_at, 1558143_a_at, 225606_at,
1553088_a_at, 208536_s_at, and 1555372_at).
BH3 proﬁling and intracellular ﬂow cytometry
Intracellular BH3 proﬁling was performed as described
earlier by measuring mitochondrial cytochrome c release
by ﬂow cytometry43. Cryopreserved pediatric ALL PDX
samples were thawed, permeabilized with digitonin and
exposed to proapoptotic BH3 peptides or venetoclax
before ﬁxation in formaldehyde. Cells were stained with
anti-cytochrome c antibody Alexa Fluor 488 (#612308,
Biolegend). The peptide-induced cytochrome c release
was quantiﬁed as median ﬂuorescence intensity (MFI)
normalized to the MFIs of alamethicin (positive control of
cytochrome c release; #BML-A150-0005, Enzo) and
DMSO (negative control). For intracellular protein
staining, cells were stained with anti-BCL-2 mAb Alexa
Fluor 488 (#59422, Cell Signaling), anti-BIM mAb Alexa
Fluor 488 (#94805, Cell Signaling), mouse mAb IgG1
Isotype Control Alexa Fluor 488 (#4878, Cell Signaling)
and rabbit IgG Isotype Control Alexa Fluor 488 (#4340,
Cell Signaling). MFIs were quantiﬁed and normalized to
the MFIs of the respective isotype controls.
Statistical analysis
Data were analyzed using GraphPad Prism software.
Mann–Whitney test was used to compare values of two
groups, linear regression to test an association of two
variables to each other, and survival analyses were per-
formed using the Kaplan–Meier method and the log-
rank test.
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